{
    "clinical_study": {
        "@rank": "107643", 
        "arm_group": {
            "arm_group_label": "Treatment (gene therapy)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive busulfan IV over 3 hours on day -2 followed by lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells IV on day 0."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies gene therapy after frontline chemotherapy in treating\n      patients with acquired immune deficiency syndrome (AIDS)-related non-Hodgkin lymphoma (NHL).\n      Placing genes for anti-human immunodeficiency virus (HIV) ribonucleic acid (RNA) into\n      stem/progenitor cells may make the body build an immune response to AIDS. Giving the\n      chemotherapy drug busulfan before gene therapy can help gene-modified cells engraft and work\n      better."
        }, 
        "brief_title": "Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma", 
        "condition": [
            "AIDS-related Diffuse Large Cell Lymphoma", 
            "AIDS-related Diffuse Mixed Cell Lymphoma", 
            "AIDS-related Diffuse Small Cleaved Cell Lymphoma", 
            "AIDS-related Immunoblastic Large Cell Lymphoma", 
            "AIDS-related Lymphoblastic Lymphoma", 
            "AIDS-related Small Noncleaved Cell Lymphoma", 
            "HIV Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, Large B-Cell, Diffuse", 
                "Lymphoma, Large-Cell, Immunoblastic", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To demonstrate the safety and feasibility of recombinant (r)HIV7-short hairpin RNA\n      targeted to the HIV-1 tat/rev (shI)-trans-active response element (TAR)-chemokine\n      cysteine-cysteine receptor 5 ribozyme (CCR5RZ)-treated hematopoietic stem progenitor cells\n      (HSPC) (lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells)\n      infusion in AIDS patients completing treatment for NHL and non-myeloablative conditioning\n      with busulfan.\n\n      II. To demonstrate the engraftment of gene-modified progeny cells following such treatment.\n\n      III. To determine if selection of these gene-modified progeny cells occurs during analytical\n      treatment interruption (ATI) of combination anti-retroviral therapy (cART).\n\n      SECONDARY OBJECTIVES:\n\n      I. To evaluate the pharmacokinetics of busulfan in patients with AIDS-related lymphoma\n      (ARL).\n\n      II. To determine the effects of HIV-1 infection on the presence of gene-marked peripheral\n      blood mononuclear cells (PBMC) as measured by woodchuck post-transcriptional regulatory\n      element (WPRE) deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) performed before,\n      during, and after ATI.\n\n      OUTLINE:\n\n      Patients receive busulfan intravenously (IV) over 3 hours on day -2 followed by lentivirus\n      vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells IV on day 0.\n\n      After completion of study treatment, patients are followed up at 1, 7, 14, and 21 days and\n      1, 2, 3, 6, 9, 12, 18, and 24 months and then annually for 13 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HIV-seropositive at or before the time of lymphoma diagnosis\n\n          -  Karnofsky performance status >= 70%\n\n          -  Biopsy proven NHL, including plasmablastic lymphoma and primary effusion lymphoma but\n             not T-cell lymphoma; tissue histology will be reviewed at City of Hope (COH)\n\n          -  Between 28 days and 3 years from completion of frontline chemotherapy\n\n          -  Complete remission documented by computed tomography (CT) or positron emission\n             tomography (PET)-CT scan within 3 months of study entry\n\n          -  No diagnosed psychosocial conditions that would hinder study compliance and follow-up\n\n          -  Pretreatment serum glutamic oxaloacetic transaminase (SGOT), serum glutamate pyruvate\n             transaminase (SGPT) =< 2.5 x institutional upper limit of normal (ULN)\n\n          -  Pretreatment serum bilirubin =< 2.5 x institutional ULN or\n\n          -  Total bilirubin < 4.5 mg/dl with direct fraction =< 0.3 mg/dl in patients for whom\n             these abnormalities are felt to be due to protease inhibitor therapy\n\n          -  Serum creatinine < 2 x the institutional ULN and a 24 hour urine creatinine clearance\n             > 60 cc/min\n\n          -  Absence of clinically significant cardiomyopathy, congestive heart failure; cardiac\n             ejection fraction has to be >=50%\n\n          -  Spirometry diffusion capacity (diffusion capacity of the lung for carbon monoxide\n             [DLCO]) >= 50%\n\n          -  If the subject is female and of child-bearing potential, subject must have negative\n             serum or urine pregnancy test within 7 days of treatment with research agent; men\n             with partners of child-bearing potential and women of child-bearing potential must be\n             willing to use medically effective birth control methods, e.g. contraceptive pill,\n             condom, or diaphragm and continue this for one year post HSPC infusion\n\n          -  Subjects must be on a prophylactic regimen for Pneumocystis carinii pneumonia, or\n             agree to begin such treatment, if the cluster of differentiation (CD)4 counts are <\n             200 cells/uL\n\n          -  SECONDARY ELIGIBILITY CRITERIA FOR GENE-MODIFIED HSPC INFUSION\n\n          -  Subjects must complete the filgrastim (G-CSF)/plerixafor mobilization of peripheral\n             blood progenitor cells and must have collected at least 7.5 x 10^6 CD34+ cells/kg,\n             sufficient for preparation of both, a back-up of 2.5 x 10^6 CD34+ cells and the\n             research product\n\n          -  Research product must pass all release tests\n\n          -  All subjects must have the ability to understand and the willingness to sign a\n             written informed consent\n\n        Exclusion Criteria:\n\n          -  Any AIDS-related opportunistic infection occurring within the past year and for which\n             treatment has been unsuccessful would be considered exclusionary, but this is done on\n             a case-by-case basis as determined by the principal investigator\n\n          -  Active cytomegalovirus (CMV) retinitis or other active CMV-related organ dysfunction;\n             patients with a history of treated CMV infection are not excluded\n\n          -  Patients who are hepatitis C virus (HCV) antibody positive or hepatitis B virus (HBV)\n             surface antigen positive and HBV DNA positive\n\n          -  Pregnant or nursing women\n\n          -  Active central nervous system (CNS) lymphoma; patients with a history of positive\n             cerebrospinal fluid cytology that has become negative with intrathecal chemotherapy\n             are eligible\n\n          -  Any history of HIV-1 associated encephalopathy; dementia of any kind; seizures in the\n             past 12 months; any perceived inability to directly provide informed consent (note:\n             consent may not be obtained by means of a legal guardian)\n\n          -  Any medical or physical contraindication or any other inability to undergo HSPC\n             collection\n\n          -  Patients should not have any uncontrolled illness including ongoing or active\n             infection\n\n          -  Patients may not be receiving any other investigational agents, or concurrent\n             biological, chemotherapy, or radiation therapy\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to G-CSF/filgrastim (Escherichia [E] coli producing cell line),\n             plerixafor or busulfan\n\n          -  Patients with other active malignancies other than skin cancers are ineligible for\n             this study\n\n          -  Subjects, who in the opinion of the investigator, may not be able to comply with the\n             safety monitoring requirements of the study will be considered non-compliant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01961063", 
            "org_study_id": "13282", 
            "secondary_id": [
                "NCI-2013-01728", 
                "13282", 
                "P30CA033572"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (gene therapy)", 
                "description": "Given IV", 
                "intervention_name": "busulfan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BSF", 
                    "BU", 
                    "Misulfan", 
                    "Mitosan", 
                    "Myeloleukon"
                ]
            }, 
            {
                "arm_group_label": "Treatment (gene therapy)", 
                "description": "Given IV", 
                "intervention_name": "lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells", 
                "intervention_type": "Biological", 
                "other_name": "lentivirus-transduced hematopoietic progenitor cells"
            }, 
            {
                "arm_group_label": "Treatment (gene therapy)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (gene therapy)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Busulfan"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 21, 2014", 
        "location": {
            "contact": {
                "email": "AKrishnan@coh.org", 
                "last_name": "Amrita Y. Krishnan", 
                "phone": "626-256-4673"
            }, 
            "facility": {
                "address": {
                    "city": "Duarte", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91010"
                }, 
                "name": "City of Hope Medical Center"
            }, 
            "investigator": {
                "last_name": "Amrita Y. Krishnan", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Feasibility of Gene Transfer After Frontline Chemotherapy for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs", 
        "overall_official": {
            "affiliation": "City of Hope Medical Center", 
            "last_name": "Amrita Krishnan", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2030", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Tables will be created to summarize these toxicities and side effects.", 
                "measure": "Procedure related toxicity as determined by adverse events (AE) grading scale using the Common Terminology Criteria for Adverse Events CTCAE) version v4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 15 years"
            }, 
            {
                "measure": "Time to Absolute Neutrophil Count (ANC) >= 500/uL", 
                "safety_issue": "Yes", 
                "time_frame": "First 30 days"
            }, 
            {
                "measure": "Time to platelet recovery to >= 50,000/uL", 
                "safety_issue": "Yes", 
                "time_frame": "First 90 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01961063"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PCR-based assay on PBMC", 
                "measure": "Evidence for and duration of vector-marked PBMC/marrow cells", 
                "safety_issue": "No", 
                "time_frame": "Up to 15 years"
            }, 
            {
                "description": "PCR-based assay on FACS-sorted cells", 
                "measure": "Expression of the RNA transgenes in lineage-specific progeny of the transduced cells", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "HIV proviral DNA, HIV RNA single copy, and 2-LTR circle DNA from PBMCs", 
                "measure": "Effect of ATI on HIV markers and CD4 count", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 15 years"
            }, 
            {
                "description": "Cmax, CLsys, Vd, t1/2's, AUC", 
                "measure": "Pharmacokinetics of busulfan", 
                "safety_issue": "No", 
                "time_frame": "Day -2 at 0 hours (pre-infusion); 3 hours (just before end of infusion); and at 4, 5, and 6 hours and day -1 at 24 hours"
            }, 
            {
                "description": "The number and type of cells will be determined by fluorescence activated cell sorting (FACS) analysis of the final cell product. The minimum target number of CD34+ cells for collection is 7.5 x 10e6 cells/kg and, in the final transduced cell product, the number of CD34+ cells must be >= 2.0 x 10e6 CD34+ cells/kg with total viability >= 70%.", 
                "measure": "Ability to obtain suitable numbers of transduced HSPC for engraftment", 
                "safety_issue": "No", 
                "time_frame": "Pre-infusion of the investigational drug"
            }, 
            {
                "description": "Release assays", 
                "measure": "Feasibility of product manufacturing as evidenced by product release", 
                "safety_issue": "No", 
                "time_frame": "Pre-infusion of the investigational drug"
            }
        ], 
        "source": "City of Hope Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "City of Hope Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}